Lung Cancer Therapeutics Market Size Worth USD 57.69 Billion in 2032 | Emergen Research

Increasing adoption of unhealthy lifestyle and rising demand for targeted therapies are key factors driving market revenue growth

Vancouver, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global lung cancer therapeutics market size was USD 28.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the forecast period. Key drivers for this growth include the escalating adoption of unhealthy lifestyles, particularly persistent tobacco use in certain regions, and an increasing demand for targeted therapies.

The continued prevalence of tobacco use, a major modifiable risk factor for lung cancer, remains a challenge, necessitating advanced and accessible lung cancer therapeutics. Moreover, the rising demand for targeted therapies, known for their effectiveness in inhibiting cancer growth while minimizing side effects, is contributing to the market's positive trajectory.

However, the market faces constraints due to the side effects associated with lung cancer treatment. Nausea, fatigue, and other discomforts impact patients' well-being, potentially leading to treatment discontinuation and reducing therapy effectiveness. This poses challenges to healthcare providers, increasing the resource burden and straining healthcare systems.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @

A notable trend in the field is the development of targeted therapies for specific genetic mutations in lung cancer patients. The emergence of precision medicine has led to drugs designed to target specific mutations, such as Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) rearrangements, offering personalized and effective treatments. Targeted therapy accounted for the largest revenue share in 2022, underscoring the shift towards more patient-friendly options.

Therapy Insights: Targeted Therapy Leads, Chemotherapy Shows Promise

In 2022, targeted therapy dominated the market, accounting for the largest revenue share. The precision of targeted therapies in addressing specific genetic abnormalities within tumors, while minimizing collateral damage to healthy cells, enhances treatment effectiveness and improves patient quality of life.

The chemotherapy segment is expected to witness moderately fast revenue growth due to its versatility in addressing various lung cancer types. Chemotherapy's broad applicability, particularly in small cell lung cancer and advanced stages of Non-Small Cell Lung Cancer (NSCLC), ensures a consistent demand.

Distribution Insights: Hospitals Dominate, Online Pharmacies on the Rise

Hospitals are expected to hold a significantly large revenue share, driven by the increasing number of hospitals offering advanced therapeutics and healthcare services. The presence of healthcare professionals in hospitals facilitates proper drug dosage and comprehensive care. Hospitals remain the preferred choice for administering cancer treatments.

Online pharmacies are poised for steady growth, catering to the rising trend of homecare settings for cancer patients. The convenience of online pharmacies allows patients to receive prescribed treatments without the need for physical visits. This is crucial, especially for patients dealing with compromised health and weakened immune systems.

Regional Insights: North America Leads, Europe and Asia Pacific Show Promise

North America accounted for the largest revenue share in 2022, attributed to the region's advanced healthcare infrastructure and access to cutting-edge medical technologies. The approval of Mirati's lung cancer treatment by the US FDA highlights the region's commitment to addressing the needs of individuals with lung cancer.

The Europe market is expected to register the fastest revenue growth, driven by advancements in screening technologies, particularly the adoption of low-dose Computed Tomography (CT) for lung cancer screening. The Asia Pacific market is poised for considerable growth due to the rising prevalence of smoking, increased government investments in healthcare facilities, and expanding healthcare insurance coverage.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @

Scope of Research

Report DetailsOutcome
Market Size in 2022USD 28.00 Billion
CAGR (2023–2032)7.7%
Revenue Forecast To 2032USD 57.69 Billion
Base Year For Estimation2022
Historical Data2019-2021
Forecast Period2023–2032
Quantitative UnitsRevenue in USD Billion and CAGR in % from 2023 to 2032
Report CoverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Coveredtherapy, distribution, cancer, molecule, mode of administration, type, end-use, and region
Regional ScopeNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country ScopeU.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa
Key Companies ProfiledChurch & Dwight Co., Inc., GlaxoSmithKline plc. , Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd., Novartis AG, Lily, AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, Sanofi, Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company (US), Millennium Pharmaceuticals, Inc., and Celgene Corporation
Customization Scope10 hours of free customization and expert consultation

Major Companies and Competitive Landscape

The global lung cancer therapeutics market is moderately fragmented, with many large and medium-sized players accounting for majority of market revenue. Major businesses are using a variety of tactics, making mergers and acquisitions, strategic agreements, and contracts, as well as creating, experimenting with, and introducing more efficient lung cancer therapeutics solutions in the market.

Some major players included in the global lung cancer therapeutics market report are:

  • Church & Dwight Co., Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Novartis AG, Lily.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company (US)
  • Millennium Pharmaceuticals, Inc.
  • Celgene Corporation

Strategic Development

  • On 10 July, 2023, Iovance Biotherapeutics announced positive regulatory and clinical updates regarding its Phase 2 IOV-LUN-202 trial for LN-145 TIL therapy in post-anti-PD-1 advanced NSCLC. During discussions with the U.S. FDA, the agency expressed positive feedback on the trial design, indicating it may be suitable for accelerated approval. Preliminary clinical data from the IOV-LUN-202 trial showed a 26.1% Objective Response Rate (ORR) in post-anti-PD-1 NSCLC patients. Iovance plans to enroll around 120 patients in the trial, with expected completion in the second half of 2024. The company is also preparing for discussions with the FDA on a randomized confirmatory trial for LN-145 in frontline advanced NSCLC.
  • On 27 July, 2020, AstraZeneca announced a global collaboration with Daiichi Sankyo to develop and commercialize DS-1062, an Antibody Drug Conjugate (ADC) designed to target the trophoblast cell-surface antigen 2 (TROP2). DS-1062, under development for multiple cancer types, including NSCLC and breast cancer, leverages Daiichi Sankyo's proprietary ADC technology to selectively deliver chemotherapy to cancer cells. AstraZeneca paid USD1 billion to Daiichi Sankyo as an upfront payment, with the potential for additional conditional payments of up to USD 5 billion based on regulatory approvals and sales milestones.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @

Segments Covered in Report

For the purpose of this report, Emergen Research has segmented the global Lung cancer therapeutics market on the basis of type, application, deployment, enterprise size, component, vertical, and region:

  • Therapy Outlook (Revenue, USD Billion; 2019-2032)
    • Targeted Therapy
      1. Bevacizumab
      2. Dabrafenib/Trametinib
      3. Erlotinib Hydrochloride
      4. Osimertinib
      5. Others
    • Immunotherapy
      1. Durvalumab
      2. Nivolumab
      3. Atezolizumab
      4. Pembrolizumab
    • Chemotherapy
      1. Cisplatin
      2. Taxol
      3. Navelbine
      4. Camptosar
      1. Alimta
  • Distribution Outlook (Revenue, USD Billion; 2019-2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Cancer Outlook (Revenue, USD Billion; 2019-2032)
    • Non-Small Cell Lung Cancer (NSCLC)
    • Small Cell Lung Cancer (SCLC)
  • Molecule Outlook (Revenue, USD Billion; 2019-2032)
    • Biologics
    • Small Molecules
  • Mode of Administration Outlook (Revenue, USD Billion; 2019-2032)
    • Injectable
    • Oral
  • Type Outlook (Revenue, USD Billion; 2019-2032)
    • Acute Myeloid Leukemia (AML)
    • Chronic Myeloid Leukemia (CML)
    • Acute Lymphoblastic Leukemia (ALL)
    • Chronic Lymphocytic Leukemia (CLL)
  •       End-use Outlook (Revenue, USD Billion; 2019-2032)
    • Hospitals
    • Research Institutes
  • Regional Outlook (Revenue, USD Billion; 2019–2032)
    • North America
      1. U.S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. France
      3. UK
      4. Italy
      5. Spain
      6. Benelux
      7. Rest of Europe
    • Asia Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. UAE
      3. South Africa
      4. Turkey
      5. Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@

Curated Reports You Shouldn't Miss: Dive In Now!

Organ on a Chip Market By Type (Liver-on-Chip, Multiple Organs-on-Chips, Kidney-on-Chip, Heart-on-Chip, Lung-on-Chip, Intestine-on-Chip), By Application (Drug Discovery, Physiological Model Development, Toxicology Research), By End-Use (Pharmaceutical Firms, Research Institutes, Personal Care Industry), and By Region Forecast to 2028

Medical Electrodes Market, By Product Type (Surface Electrodes and Needle Electrodes), By Usability (Disposable and Reusable), By Modality, By Application (Cardiology, Neurophysiology, and Others), and By Region Forecast to 2030

Renal Denervation Market, By Technology (Radiofrequency, Ultrasound, Micro-infusion, and Others), By End-Use (Hospital, Specialty Clinics, and Others), and By Region Forecast to 2032

Blood-Brain Barrier (BBB) Market By Application (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer), By Technology (Bispecific Antibody RMT Approach, Trojan Horse Approach, Increasing Permeability, Passive Diffusion, Others), By End-Use (Hospitals, Surgical centers, Research Institutes, Others), and By Region Forecast to 2028

Durable Medical Equipment Market, By Product (Bathroom Safety Devices and Medical Furniture, Personal Mobility Devices, and Others), By End-use (Hospitals, Clinics, and Others), By Region Forecast to 2032

 About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756


Explore Our Blogs and Insights Section: